- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- USWM, LLC (dba US WorldMeds)
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 27
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute LAO
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 26
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma
- Interventions
- pazopanib
- Drug
- Lead sponsor
- Vector Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Post Falls, Idaho + 6 more
- Conditions
- Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Cancer
- Interventions
- cyproheptadine hydrochloride, placebo
- Drug · Other
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 14
- States / cities
- Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
- Conditions
- Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Mirdametinib, Palbociclib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Interventions
- Avelumab, Trabectedin
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (Lete-Cel (GSK3377794)), Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
- Interventions
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification, Myxoid Liposarcoma, CIC-Rearranged Sarcoma
- Interventions
- BTX-A51
- Drug
- Lead sponsor
- Michael Wagner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms
- Interventions
- GSK3845097, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin, Echocardiography Test, Multigated Acquisition Scan, Pembrolizumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 246
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Dublin, California + 200 more
- Conditions
- Liposarcoma, Metastatic Liposarcoma
- Interventions
- MGCD516
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York
- Conditions
- Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
- Drug · Procedure · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Liposarcoma
- Interventions
- efatutazone
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 127
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • New Haven, Connecticut + 75 more
- Conditions
- Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma
- Interventions
- Sunitinib Malate (SU011248)
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Dedifferentiated Liposarcoma
- Interventions
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 146 more
- Conditions
- Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 651
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 402 more
- Conditions
- Dedifferentiated Liposarcoma
- Interventions
- Selinexor, Placebo
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
- Conditions
- Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Neoplasms
- Interventions
- Letetresgene autoleucel (lete-cel, GSK3377794), Fludarabine, Cyclophosphamide
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Neoplasms
- Interventions
- GSK3901961, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more